Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen

Novo Nordisk

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.

5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates

Only 21% of parents of children under five said in February that they'd vaccinate their child “right away.”

Moderna Asks FDA To Authorize Covid Vaccines For Young Kids — But Most Parents Are In No Rush, Polls Suggest

If authorized, it will be the first COVID vaccine available for very young children.

Moderna Asks FDA to Authorize COVID Vaccine for Kids Under 6

Moderna (MRNA) stock could get a boost after the company revealed an application with the FDA for its Covid-19 vaccine in kids. The post MRNA Stock Alert: 11 Things to Know as Moderna Seeks FDA Vaccine Approval for Kids appeared first on InvestorPlace.

MRNA Stock Alert: 11 Things to Know as Moderna Seeks FDA Vaccine Approval for Kids

Moderna said it had applied to the FDA for emergency-use authorization for its COVID-19 vaccine for kids between 6 months and 6 years.

Moderna asks FDA to OK its coronavirus shot for kids under 6

Moderna is seeking emergency use authorization for its vaccine in children ages 6 months through five years which, if granted, will mark the first time Covid shots are available to young children.

Moderna Asks FDA To Authorize Covid Vaccine In Children As Young As 6 Months

Shares of Moderna Inc. MRNA, -2.30% gained 2.1% in premarket trading on Thursday after the company said it filed for authorization of its COVID-19 vaccine in children between the ages of 6 months and 6 years old. The submission is set to be completed next week, and is broken out into two categories: 6 month olds to 2 year olds, for which the vaccine has a 51% efficacy rate, and children between the ages of 2 and 6 years old, for which the efficacy rate was 37%.

Moderna asks the FDA to authorize its COVID-19 vaccine in young children

Submission to Regulators Globally Is Based on Phase 2/3 Studies of mRNA-1273 in Young Children CAMBRIDGE, MA / ACCESSWIRE / April 28, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request for emergency use authorization (EUA) for its COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age to the U.S. Food and Drug Administration and that similar requests are underway with international regulatory authorities. The requests are based on a 25 μg two-dose primary series of mRNA-1273.

Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

The FDA has promised to move quickly to authorize shots for infants, toddlers and preschoolers once the vaccine makers submit complete applications.

Moderna asks FDA to authorize Covid vaccine for kids under 6 years old

The head of the World Health Organization will present a shareholder resolution at the annual meeting of Moderna Inc on Thursday, a rare step into investor advocacy by the United Nations agency.

WHO says pandemic justifies leader's pitch at Moderna meeting

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amazon

Broadcom

Bio-Techne

Visa

Making good stock picks is challenging at any time. But these days, investors must be wary of companies that are vulnerable to higher-for-longer inflation, as well as lingering supply-chain disruptions, rising interest rates and the scary geopolitical situation in eastern Europe.

5 Stock Picks With Bulletproof Profit Margins

Shares of Moderna Inc. MRNA, +1.85% were down 0.4% in premarket trading on Wednesday after the company said it hired a new chief commercial officer. Arpa Garay, who is set to Moderna on May 31, most recently served as chief marketing officer for Merck & Co. Inc.'s MRK, -0.82% Human Health business.

Moderna hires chief commercial officer

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join Moderna as Chief Commercial Officer, effective Monday, May 31, 2022. She will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel.

Arpa Garay Joins Moderna as Chief Commercial Officer

It could put Novavax a step ahead in a post-pandemic world.

Does This News From Novavax Mean Trouble for Moderna?

Pfizer

Demand for doses of the coronavirus vaccine isn't as reliably high as it once was.

Did Johnson & Johnson's CFO Just Spell Trouble for Moderna and Pfizer?

Shares of vaccine companies, including Moderna Inc (NASDAQ: MRNA), are trading higher amid COVID-19 concerns due to rising cases in China. Rising COVID-19 cases in China's capital Beijing and Shanghai, where enforcement of a strict "zero-COVID" policy is ongoing, have drawn global.

What's Going On With Moderna Shares?

American Airlines

Advisorshares Hotel ETF

Defiance Hotel Airline and Cruise ETF

Advisorshares Restaurant ETF

US Global Jets ETF

ALPS Global Travel Beneficiaries ETF

Novavax

SonicShares Airlines, Hotels, Cruise Lines ETF

As the pandemic is slowly turning into an endemic, leisure and travel stocks have flied higher.

Time for Reopening-Friendly Travel & Leisure ETFs?

Could this once high-flying stock rebound?

2 Reasons to Buy Moderna, and 1 Reason to Sell

DigitalOcean Holdings

NVIDIA

These stocks could put up some big numbers if the market sees them in the same light as the investment bank analysts who follow them.

3 Growth Stocks Wall Street Thinks Could Gain 60% or More

BioCryst Pharmaceuticals

BioNTech SE

Exelixis

iTeos Therapeutics, Inc.

Merus

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

7 Top-Rated Biotech Stocks to Buy for Q2

Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.

Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab

PayPal

Select analysts believe these well-known, high-growth stocks could soar.

3 Nasdaq 100 Stocks With Up to 206% Upside, According to Wall Street

Moderna Inc. MRNA, -3.22% said Tuesday that it expects to have clinical data for a COVID-19 booster that protects against the original strain of the virus as well as omicron by the end of June, with the expectation that this would be the shot that is rolled out to Americans in the fall.

Moderna is developing a COVID-19 booster that protects against omicron and the original virus

A 50-microgram dose of Moderna's new vaccine doubled the antibodies against the omicron variant six months after administration.

News for Moderna Stock (MRNA)